The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use
欧洲药品管理局批准阿昔替尼（Inlyta）用于治疗既往接受舒尼替尼或细胞因子治疗失败的晚期肾细胞癌：人用药品委员会科学评估摘要
期刊:Oncologist
影响因子:4.2
doi:10.1634/theoncologist.2014-0177
Tzogani, Kyriaki; Skibeli, Venke; Westgaard, Ingunn; Dalhus, Marianne; Thoresen, Hege; Slot, Karsten Bruins; Damkier, Per; Hofland, Kenneth; Borregaard, Jeanett; Ersbøll, Jens; Salmonson, Tomas; Pieters, Ronny; Sylvester, Richard; Mickisch, Gerald; Bergh, Jonas; Pignatti, Francesco
